{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,25]],"date-time":"2026-10-25T12:53:20Z","timestamp":1792932800825,"version":"4.5.0"},"reference-count":97,"publisher":"BMJ","issue":"7","license":[{"start":{"date-parts":[[2022,7,4]],"date-time":"2022-07-04T00:00:00Z","timestamp":1656892800000},"content-version":"unspecified","delay-in-days":3,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100000764","name":"King's College London","doi-asserted-by":"publisher","award":["International Scholarship (RDPL3PRPCA - 2019-20)"],"award-info":[{"award-number":["International Scholarship (RDPL3PRPCA - 2019-20)"]}],"id":[{"id":"10.13039\/501100000764","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["BMJ Open"],"accepted":{"date-parts":[[2022,5,31]]},"published-print":{"date-parts":[[2022,7]]},"abstract":"<jats:sec>\n                    <jats:title>Objectives<\/jats:title>\n                    <jats:p>To estimate the overall prevalence of androgenic-anabolic steroids (AAS) users seeking support from physicians. Secondary objectives are to compare this prevalence in different locations and among subpopulations of AAS users, and to discuss some of the factors that could have influenced the engagement of AAS users with physicians.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Design<\/jats:title>\n                    <jats:p>Systematic review and meta-analysis.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Data sources<\/jats:title>\n                    <jats:p>MEDLINE, PsycINFO, Web of Science and SciELO were searched in January 2022.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Eligibility criteria<\/jats:title>\n                    <jats:p>Quantitative and qualitative studies reporting the number of AAS users who sought support from physicians, with no restrictions of language or time of publication.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Data extraction and synthesis<\/jats:title>\n                    <jats:p>Two independent reviewers extracted data and assessed the quality of studies, including publication bias. A random-effects meta-analysis was performed to estimate the overall prevalence of AAS users seeking support from physicians, followed by pooled prevalence rates by studies\u2019 location and the subpopulation of AAS users.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>We identified 36 studies published between 1988 and 2021, involving 10\u2009101 AAS users. The estimated overall prevalence of AAS users seeking support from physicians is 37.12% (95% CI 29.71% to 44.52%). Higher prevalence rates were observed in studies from Australia (67.27%; 95%\u2009CI 42.29% to 87.25%) and among clients of the needle and syringe exchange programme (54.13%; 95%\u2009CI 36.41% to 71.84%). The lowest prevalence was observed among adolescent AAS users (17.27%; 95%\u2009CI 4.80% to 29.74%).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Our findings suggest that about one-third of AAS users seek support from physicians, with remarkable differences between locations and subpopulations of AAS users. Further studies should investigate the factors influencing the engagement of AAS users with physicians.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>PROSPERO registration number<\/jats:title>\n                    <jats:p>CRD42020177919.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1136\/bmjopen-2021-056445","type":"journal-article","created":{"date-parts":[[2022,7,4]],"date-time":"2022-07-04T12:06:00Z","timestamp":1656936360000},"page":"e056445","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":40,"title":["Prevalence of anabolic steroid users seeking support from physicians: a systematic review and meta-analysis"],"prefix":"10.1136","volume":"12","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-5054-2834","authenticated-orcid":false,"given":"Julio Mario Xerfan","family":"Amaral","sequence":"first","affiliation":[{"name":"Addictions, King's College London Institute of Psychiatry Psychology and Neuroscience, London, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2080-9865","authenticated-orcid":false,"given":"Andreas","family":"Kimerg\u00e5rd","sequence":"additional","affiliation":[{"name":"Addictions, King's College London Institute of Psychiatry Psychology and Neuroscience, London, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9511-7230","authenticated-orcid":false,"given":"Paolo","family":"Deluca","sequence":"additional","affiliation":[{"name":"Addictions, King's College London Institute of Psychiatry Psychology and Neuroscience, London, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"239","published-online":{"date-parts":[[2022,7,4]]},"reference":[{"key":"2025121410135776000_12.7.e056445.1","doi-asserted-by":"crossref","unstructured":"Nieschlag E , Behre HM . Clinical use of testosterone in hypogonadism and other conditions. In: Testosterone: action, deficiency, substitution. Cambridge UK: Cambridge University Press, 2016: 292\u2013308.","DOI":"10.1017\/CBO9781139003353.015"},{"key":"2025121410135776000_12.7.e056445.2","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1001\/jamapsychiatry.2018.2734","article-title":"Association of testosterone treatment with alleviation of depressive symptoms in men: a systematic review and meta-analysis","volume":"76","author":"Walther","year":"2019","journal-title":"JAMA Psychiatry"},{"key":"2025121410135776000_12.7.e056445.3","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1016\/j.steroids.2018.08.002","article-title":"Potential application of testosterone replacement therapy as treatment for obesity and type 2 diabetes in men","volume":"138","author":"Fink","year":"2018","journal-title":"Steroids"},{"key":"2025121410135776000_12.7.e056445.4","doi-asserted-by":"publisher","DOI":"10.1136\/bjsm.31.1.54"},{"key":"2025121410135776000_12.7.e056445.5","unstructured":"Begley E , McVeigh J , Hope V . Image and performance enhancing drugs - 2016 National survey results. Liverpool John Moores University, 2017."},{"key":"2025121410135776000_12.7.e056445.6","doi-asserted-by":"publisher","DOI":"10.1210\/er.2013-1058"},{"key":"2025121410135776000_12.7.e056445.7","doi-asserted-by":"publisher","DOI":"10.1111\/j.1360-0443.2004.00781.x"},{"key":"2025121410135776000_12.7.e056445.8","unstructured":"Hope V , Leavy C , Morgan G , et al . Facilitators and barriers to health care access amongst people using image and performance enhancing drugs in Wales: findings and outcomes. Public Health Wales, 2020."},{"key":"2025121410135776000_12.7.e056445.9","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1080\/00913847.2018.1526626","article-title":"Anabolic-androgenic steroids: procurement and administration practices of doping athletes","volume":"47","author":"Fink","year":"2019","journal-title":"Phys Sportsmed"},{"key":"2025121410135776000_12.7.e056445.10","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1016\/j.peh.2016.11.002","article-title":"Post-cycle therapy for performance and image enhancing drug users: a qualitative investigation","volume":"5","author":"Griffiths","year":"2017","journal-title":"Perform Enhanc Health"},{"key":"2025121410135776000_12.7.e056445.11","doi-asserted-by":"crossref","unstructured":"Greenway P , Greenway M . General practitioner knowledge of prohibited substances in sport. 1997;1:129\u201331.","DOI":"10.1136\/bjsm.31.2.129"},{"key":"2025121410135776000_12.7.e056445.12","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1080\/09595239700186761","article-title":"General practitioners' views and knowledge about anabolic steroid use--survey of GPs in a high prevalence area","volume":"16","author":"Gupta","year":"1997","journal-title":"Drug Alcohol Rev"},{"key":"2025121410135776000_12.7.e056445.13","doi-asserted-by":"publisher","DOI":"10.1177\/2042098619854010"},{"key":"2025121410135776000_12.7.e056445.14","first-page":"8","article-title":"General practitioners knowledge, practice and training requirements in relation to doping in sport","volume":"102","author":"Woods","year":"2009","journal-title":"Ir Med J"},{"key":"2025121410135776000_12.7.e056445.15","doi-asserted-by":"publisher","DOI":"10.1016\/j.bodyim.2015.06.001"},{"key":"2025121410135776000_12.7.e056445.16","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s12954-017-0176-8","article-title":"Information sought, information shared: exploring performance and image enhancing drug user-facilitated harm reduction information in online forums","volume":"14","author":"Tighe","year":"2017","journal-title":"Harm Reduct J"},{"key":"2025121410135776000_12.7.e056445.17","doi-asserted-by":"crossref","DOI":"10.1186\/s12889-019-7288-x","article-title":"Support for people who use anabolic androgenic steroids: a systematic scoping review into what they want and what they access","volume":"19","author":"Harvey","year":"2019","journal-title":"BMC Public Health"},{"key":"2025121410135776000_12.7.e056445.18","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1016\/j.drugpo.2018.02.022","article-title":"Identifying a typology of men who use anabolic androgenic steroids (AAS)","volume":"55","author":"Zahnow","year":"2018","journal-title":"Int J Drug Policy"},{"key":"2025121410135776000_12.7.e056445.19","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1177\/0091450917694268","article-title":"Adverse effects, health service engagement, and service satisfaction among anabolic androgenic steroid users","volume":"44","author":"Zahnow","year":"2017","journal-title":"Contemp Drug Probl"},{"key":"2025121410135776000_12.7.e056445.20","first-page":"295","article-title":"Outline of a typology of men\u2019s use of anabolic androgenic steroids in fitness and strength training environments*","volume":"24","author":"Christiansen","year":"2017","journal-title":"Drugs"},{"key":"2025121410135776000_12.7.e056445.21","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1097\/HRP.0000000000000211","article-title":"Competitive bodybuilding: fitness, pathology, or both?","volume":"27","author":"Steele","year":"2019","journal-title":"Harv Rev Psychiatry"},{"key":"2025121410135776000_12.7.e056445.22","doi-asserted-by":"crossref","unstructured":"Amaral JMX , Deslandes AC , Padilha MC . No association between psychiatric symptoms and doses of anabolic steroids in a cohort of male and female bodybuilders. Drug Test Anal 2022:1\u201310.doi:10.1002\/dta.3230","DOI":"10.1002\/dta.3230"},{"key":"2025121410135776000_12.7.e056445.23","doi-asserted-by":"publisher","DOI":"10.1136\/bmjopen-2013-003207"},{"key":"2025121410135776000_12.7.e056445.24","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1136\/bmjopen-2014-005275","article-title":"Environments, risk and health harms: a qualitative investigation into the illicit use of anabolic steroids among people using harm reduction services in the UK","volume":"4","author":"Kimerg\u00e5rd","year":"2014","journal-title":"BMJ Open"},{"key":"2025121410135776000_12.7.e056445.25","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.b2535"},{"key":"2025121410135776000_12.7.e056445.26","doi-asserted-by":"publisher","DOI":"10.1186\/s13643-016-0384-4"},{"key":"2025121410135776000_12.7.e056445.27","doi-asserted-by":"crossref","first-page":"285","DOI":"10.3233\/EFI-180221","article-title":"The mixed methods appraisal tool (MMAT) version 2018 for information professionals and researchers","volume":"34","author":"Hong","year":"2018","journal-title":"EFI"},{"key":"2025121410135776000_12.7.e056445.28","doi-asserted-by":"publisher","DOI":"10.1016\/S0895-4356(00)00242-0"},{"key":"2025121410135776000_12.7.e056445.29","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.315.7109.629"},{"key":"2025121410135776000_12.7.e056445.30","doi-asserted-by":"publisher","DOI":"10.2307\/2533446"},{"key":"2025121410135776000_12.7.e056445.31","doi-asserted-by":"publisher","DOI":"10.1177\/0272989X05282643"},{"key":"2025121410135776000_12.7.e056445.32","doi-asserted-by":"publisher","DOI":"10.1002\/sim.1186"},{"key":"2025121410135776000_12.7.e056445.33","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.327.7414.557"},{"key":"2025121410135776000_12.7.e056445.34","doi-asserted-by":"publisher","DOI":"10.1002\/sim.1221"},{"key":"2025121410135776000_12.7.e056445.35","doi-asserted-by":"publisher","DOI":"10.1016\/j.annepidem.2014.01.009"},{"key":"2025121410135776000_12.7.e056445.36","article-title":"Prevalence, severity, and nature of preventable patient harm across medical care settings: systematic review and meta-analysis","volume":"366","author":"Panagioti","year":"2019","journal-title":"BMJ"},{"key":"2025121410135776000_12.7.e056445.37","doi-asserted-by":"publisher","DOI":"10.1002\/sim.1187"},{"key":"2025121410135776000_12.7.e056445.38","unstructured":"R Core Team . R: a language and environment for statistical computing. Vienna, Austria: R Foundation for Statistical Computing, 2022. https:\/\/www.r-project.org\/ doi:24Feb2022"},{"key":"2025121410135776000_12.7.e056445.39","doi-asserted-by":"publisher","DOI":"10.18637\/jss.v036.i11"},{"key":"2025121410135776000_12.7.e056445.40","doi-asserted-by":"crossref","first-page":"152","DOI":"10.32463\/rphs.2019.v05i02.06","article-title":"Usage and perceptions of anabolic-androgenic steroids among male gym attendees in Quetta city, Pakistan\u2013a descriptive analysis","volume":"05","author":"Uddin","year":"2019","journal-title":"RPHS"},{"key":"2025121410135776000_12.7.e056445.41","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1080\/08897077.2019.1635954","article-title":"Health care engagement behaviors of men who use performance- and image-enhancing drugs in Australia","volume":"41","author":"Jacka","year":"2020","journal-title":"Subst Abus"},{"key":"2025121410135776000_12.7.e056445.42","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2648.2004.03331.x"},{"key":"2025121410135776000_12.7.e056445.43","doi-asserted-by":"crossref","first-page":"217","DOI":"10.3109\/10826089909035644","article-title":"Naturalistic observation of athletic drug-use patterns and behavior in professional-caliber bodybuilders","volume":"34","author":"Aug\u00e9","year":"1999","journal-title":"Subst Use Misuse"},{"key":"2025121410135776000_12.7.e056445.44","unstructured":"Dennington V , Humeniuk R , Newcombe D . Qualitative field study for users of performance and image enhancing drug. Drug & Alcohol Services South Australia 2007:1\u201356."},{"key":"2025121410135776000_12.7.e056445.45","doi-asserted-by":"publisher","DOI":"10.1111\/dar.12363"},{"key":"#cr-split#-2025121410135776000_12.7.e056445.46.1","unstructured":"NSW legislation . Crimes and other legislation amendment (Assault and Intoxication) Act 2014 No 2 - NSW Legislation. Australia"},{"key":"#cr-split#-2025121410135776000_12.7.e056445.46.2","unstructured":"2022. https:\/\/legislation.nsw.gov.au\/view\/html\/inforce\/2014-01-31\/act-2014-002#sch.4 [Accessed 26 Feb 2022]."},{"key":"2025121410135776000_12.7.e056445.47","unstructured":"101st Congress . Hr 4658: anabolic steroids control act of 1990. USA; 2022. https:\/\/www.congress.gov\/bill\/101st-congress\/house-bill\/4658 [Accessed 26 Feb 2022]."},{"key":"2025121410135776000_12.7.e056445.48","unstructured":"Legislation . Misuse of drugs act 1971. UK; 2022. https:\/\/www.legislation.gov.uk\/ukpga\/1971\/38\/1996-09-01 [Accessed 26 Feb 2022]."},{"key":"2025121410135776000_12.7.e056445.49","unstructured":"Presid\u00eancia da Rep\u00fablica Casa Civil . L9965. Brazil; 2022. http:\/\/www.planalto.gov.br\/ccivil_03\/leis\/l9965.htm [Accessed 26 Feb 2022]."},{"key":"2025121410135776000_12.7.e056445.50","unstructured":"Hyat K . Dealing with DOPE in Pakistan sports, 2022. Available: https:\/\/www.thenews.com.pk\/tns\/detail\/566718-dealing-dope-pakistan-sports [Accessed 26 Feb 2022]."},{"key":"2025121410135776000_12.7.e056445.51","unstructured":"Billinghurst T . Steroids: \u201cEveryone in the gym uses them\u201d | Health \u2013 Gulf News, 2022. Available: https:\/\/gulfnews.com\/uae\/health\/steroids-everyone-in-the-gym-uses-them-1.1282654 [Accessed 26 Feb 2022]."},{"key":"2025121410135776000_12.7.e056445.52","unstructured":"Al-Ghalib E . Despite ban, anabolic steroids are available under the counter, 2022. Available: https:\/\/www.arabnews.com\/node\/265116 [Accessed 26 Feb 2022]."},{"key":"2025121410135776000_12.7.e056445.53","unstructured":"Mashasha T . \u2018Ripped\u2019 and \u2018Roids\u2019: Muscularity and Illegal Use of Anabolic-Androgenic Steroids \u2013 Blog \u2013 SaferSpaces, 2022. Available: https:\/\/www.saferspaces.org.za\/blog\/entry\/ripped-and-roids-muscularity-and-illegal-use-of-anabolic-androgenic-steroid [Accessed 26 Feb 2022]."},{"key":"2025121410135776000_12.7.e056445.54","unstructured":"Legislative . The narcotic, drugs and psychotropic substances act, 1985. India; 1985. https:\/\/legislative.gov.in\/sites\/default\/files\/A1985-61.pdf [Accessed 26 Feb 2022]."},{"key":"2025121410135776000_12.7.e056445.55","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1007\/s15006-013-1052-4","article-title":"Recreational athletes and doping--a survey in 11 gyms in the area of Frankfurt\/Main","volume":"155 Suppl 2","author":"Raschka","year":"2013","journal-title":"MMW Fortschr Med"},{"key":"2025121410135776000_12.7.e056445.56","doi-asserted-by":"publisher","DOI":"10.1016\/j.drugalcdep.2005.05.013"},{"key":"2025121410135776000_12.7.e056445.57","first-page":"261","article-title":"Doping in recreation: public view versus declared use of aas among people practising various sports (a study of Poznan gyms and fitness clubs patrons)","volume":"17","author":"Posiada\u0142a","year":"2010","journal-title":"Stud Phys Cult Tour"},{"key":"2025121410135776000_12.7.e056445.58","unstructured":"Bundesamt f\u00fcr Justiz . AntiDopG - Gesetz gegen Doping im Sport. Germany; 2022. https:\/\/www.gesetze-im-internet.de\/antidopg\/BJNR221010015.html [Accessed 26 Feb 2022]."},{"key":"2025121410135776000_12.7.e056445.59","unstructured":"Internetowy System Akt\u00f3w Prawnych . Ustawa Z dnia 6 wrze\u015bnia 2001 R. Prawo farmaceutyczne. Poland; 2022. https:\/\/isap.sejm.gov.pl\/isap.nsf\/DocDetails.xsp?id=WDU20011261381 [Accessed 26 Feb 2022]."},{"key":"2025121410135776000_12.7.e056445.60","unstructured":"Retsinformation . Dopingloven. Denmark; 2022. https:\/\/www.retsinformation.dk\/eli\/lta\/1999\/232 [Accessed 26 Feb 2022]."},{"key":"2025121410135776000_12.7.e056445.61","unstructured":"van de Ven K , Eu B , Jackson E . GP guide to harm minimisation for patients using non-prescribed anabolic-androgenic steroids (AAS) and other performance and image enhancing drugs (PIEDs). Sydney North Health Network; 2020. https:\/\/www.snhn.net\/steroid-harm-minimisation [Accessed 24 Feb 2022]."},{"key":"2025121410135776000_12.7.e056445.62","first-page":"400","article-title":"\u201cNo pain, no gainz\u201d? Performance and image-enhancing drugs, health effects and information seeking","volume":"24","author":"Rowe","year":"2017","journal-title":"Drugs"},{"key":"2025121410135776000_12.7.e056445.63","first-page":"278","article-title":"Anabolic steroids in the UK: an increasing issue for public health","volume":"24","author":"McVeigh","year":"2017","journal-title":"Drugs"},{"key":"2025121410135776000_12.7.e056445.64","unstructured":"NICE . Needle and syringe programmes. Public Heal Guid, 2014: 1\u201359."},{"key":"2025121410135776000_12.7.e056445.65","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1177\/1757913913519770","article-title":"Distinct patterns of health engagement among adolescents and young adults in England: implications for health services","volume":"134","author":"Hargreaves","year":"2014","journal-title":"Perspect Public Health"},{"key":"2025121410135776000_12.7.e056445.66","doi-asserted-by":"publisher","DOI":"10.1136\/heartjnl-2016-309573"},{"key":"2025121410135776000_12.7.e056445.67","doi-asserted-by":"publisher","DOI":"10.1001\/archpedi.1990.02150250111046"},{"key":"2025121410135776000_12.7.e056445.68","doi-asserted-by":"crossref","unstructured":"Tanner S , Miller D , Alongi C . Anabolic steroid use in adolescents: prevalence, motives, and knowledge of risks. vol. 5, clinical Journal of sport medicine. Clin J Sport Med 1995:108\u201315.doi:10.1097\/00042752-199504000-00007","DOI":"10.1097\/00042752-199504000-00007"},{"key":"2025121410135776000_12.7.e056445.69","doi-asserted-by":"publisher","DOI":"10.1001\/jama.1988.03410230059028"},{"key":"2025121410135776000_12.7.e056445.70","doi-asserted-by":"crossref","DOI":"10.3389\/fpsyg.2021.648467","article-title":"Enhancing the self: amateur bodybuilders making sense of experiences with appearance and performance-enhancing drugs","volume":"12","author":"Macho","year":"2021","journal-title":"Front Psychol"},{"key":"2025121410135776000_12.7.e056445.71","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3390\/socsci8030080","article-title":"Bodybuilding and fitness doping in transition. historical transformations and contemporary challenges","volume":"8","author":"Andreasson","year":"2019","journal-title":"Soc Sci"},{"key":"2025121410135776000_12.7.e056445.72","doi-asserted-by":"crossref","DOI":"10.1177\/1557988320966536","article-title":"Characteristics and attitudes of men using anabolic androgenic steroids (AAS): a survey of 2385 men","volume":"14","author":"Bonnecaze","year":"2020","journal-title":"Am J Mens Health"},{"key":"2025121410135776000_12.7.e056445.73","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s12954-019-0343-1","article-title":"Treatments for people who use anabolic androgenic steroids: a scoping review","volume":"16","author":"Bates","year":"2019","journal-title":"Harm Reduct J"},{"key":"2025121410135776000_12.7.e056445.74","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s13011-019-0206-5","article-title":"Anabolic-androgenic steroid users receiving health-related information; health problems, motivations to quit and treatment desires","volume":"14","author":"Havnes","year":"2019","journal-title":"Subst Abuse Treat Prev Policy"},{"key":"2025121410135776000_12.7.e056445.75","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1080\/00913847.1988.11709666","article-title":"Self-reported use of anabolic-androgenic steroids by elite power lifters","volume":"16","author":"Yesalis","year":"1988","journal-title":"Phys Sportsmed"},{"key":"2025121410135776000_12.7.e056445.76","doi-asserted-by":"crossref","first-page":"921","DOI":"10.1542\/peds.83.6.921","article-title":"Anabolic steroid use by male adolescents","volume":"83","author":"Johnson","year":"1989","journal-title":"Pediatrics"},{"key":"2025121410135776000_12.7.e056445.77","first-page":"2582","article-title":"Drug abuse in body builders. A questionnaire study","volume":"151","author":"Kisling","year":"1989","journal-title":"Ugeskr Laeger"},{"key":"2025121410135776000_12.7.e056445.78","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1111\/j.1365-2796.1990.tb00179.x","article-title":"Use of anabolic-androgenic steroids among body builders--frequency and attitudes","volume":"227","author":"Lindstr\u00f6m","year":"1990","journal-title":"J Intern Med"},{"key":"2025121410135776000_12.7.e056445.79","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1055\/s-2007-972681","article-title":"Indications of prevalence, practice and effects of anabolic steroid use in Great Britain","volume":"18","author":"Korkia","year":"1997","journal-title":"Int J Sports Med"},{"key":"2025121410135776000_12.7.e056445.80","doi-asserted-by":"publisher","DOI":"10.1046\/j.1360-0443.1999.941218298.x"},{"key":"2025121410135776000_12.7.e056445.81","doi-asserted-by":"crossref","first-page":"232","DOI":"10.1037\/0893-164X.13.3.232","article-title":"Anabolic\u2013androgenic steroids: user characteristics, motivations, and deterrents","volume":"13","author":"Peters","year":"1999","journal-title":"Psychology of Addictive Behaviors"},{"key":"2025121410135776000_12.7.e056445.82","doi-asserted-by":"publisher","DOI":"10.1097\/01.jsm.0000180872.22426.bb"},{"key":"2025121410135776000_12.7.e056445.83","doi-asserted-by":"publisher","DOI":"10.1249\/01.mss.0000210194.56834.5d"},{"key":"2025121410135776000_12.7.e056445.84","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/1550-2783-4-12","article-title":"A league of their own: demographics, motivations and patterns of use of 1,955 male adult non-medical anabolic steroid users in the United States","volume":"4","author":"Cohen","year":"2007","journal-title":"J Int Soc Sports Nutr"},{"key":"2025121410135776000_12.7.e056445.85","doi-asserted-by":"crossref","first-page":"75","DOI":"10.2174\/1874387000802010075","article-title":"Knowledge, attitude and practice of anabolic steroids use among gym users in Al-Ain district, United Arab Emirates","volume":"2","author":"Al-Falasi","year":"2009","journal-title":"TOSMJ"},{"key":"2025121410135776000_12.7.e056445.86","doi-asserted-by":"publisher","DOI":"10.1080\/09595230802392568"},{"key":"2025121410135776000_12.7.e056445.87","doi-asserted-by":"crossref","first-page":"114","DOI":"10.5628\/aehd.v2i2.102","article-title":"Prevalence of performance-enhancing substance use by Johannesburg male adolescents involved in competitive high school sports","volume":"2","author":"Gradidge","year":"2011","journal-title":"AEHD"},{"key":"2025121410135776000_12.7.e056445.88","doi-asserted-by":"publisher","DOI":"10.1592\/phco.31.8.757"},{"key":"2025121410135776000_12.7.e056445.89","doi-asserted-by":"crossref","first-page":"724","DOI":"10.3109\/10826084.2010.534123","article-title":"Illicit use and abuse of anabolic-androgenic steroids among Brazilian bodybuilders","volume":"46","author":"Santos","year":"2011","journal-title":"Subst Use Misuse"},{"key":"2025121410135776000_12.7.e056445.90","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1016\/j.mayocp.2015.10.027","article-title":"Heavy testosterone use among Bodybuilders: an uncommon cohort of illicit substance users","volume":"91","author":"Westerman","year":"2016","journal-title":"Mayo Clin Proc"},{"key":"2025121410135776000_12.7.e056445.91","doi-asserted-by":"crossref","DOI":"10.1002\/hup.2619","article-title":"The use of supplements and performance and image enhancing drugs in fitness settings: a exploratory cross-sectional investigation in the United Kingdom","volume":"32","author":"Mooney","year":"2017","journal-title":"Hum Psychopharmacol"},{"key":"2025121410135776000_12.7.e056445.92","doi-asserted-by":"crossref","first-page":"49","DOI":"10.5455\/msm.2018.30.49-52","article-title":"Prevalence, attitude, knowledge, and practice of anabolic androgenic steroid (aas) use among gym participants","volume":"30","author":"Althobiti","year":"2018","journal-title":"Mater Sociomed"},{"key":"2025121410135776000_12.7.e056445.93","first-page":"733","article-title":"Rela\u00e7\u00e3o da vigorexia com o uso de esteroides anabolizantes em praticantes de treinamento de for\u00e7a","volume":"13","author":"Macedo","year":"2019","journal-title":"Rev Bras Nutr Esp"},{"key":"2025121410135776000_12.7.e056445.94","doi-asserted-by":"crossref","first-page":"1","DOI":"10.4103\/ijpvm.IJPVM_524_17","article-title":"Anabolic androgenic steroid abuse and their health impacts\u202f: a cross-sectional study among body builders in a city of Eastern India","volume":"10","author":"Pany","year":"2019","journal-title":"Int J Prev Med"},{"key":"2025121410135776000_12.7.e056445.95","doi-asserted-by":"publisher","DOI":"10.1186\/s12889-019-6576-9"},{"key":"2025121410135776000_12.7.e056445.96","doi-asserted-by":"crossref","first-page":"645","DOI":"10.1055\/a-1342-7312","article-title":"A netnography and a survey on doping use among competitive doping-untested strength-sport athletes","volume":"42","author":"Jokipalo","year":"2021","journal-title":"Int J Sports Med"}],"container-title":["BMJ Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/bmjopen-2021-056445","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,14]],"date-time":"2025-12-14T18:14:09Z","timestamp":1765736049000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmjopen.bmj.com\/lookup\/doi\/10.1136\/bmjopen-2021-056445"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,7]]},"references-count":97,"journal-issue":{"issue":"7","published-online":{"date-parts":[[2022,7,4]]},"published-print":{"date-parts":[[2022,7]]}},"alternative-id":["10.1136\/bmjopen-2021-056445"],"URL":"https:\/\/doi.org\/10.1136\/bmjopen-2021-056445","relation":{},"ISSN":["2044-6055","2044-6055"],"issn-type":[{"value":"2044-6055","type":"print"},{"value":"2044-6055","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,7]]}}}